6533b824fe1ef96bd12801f5
RESEARCH PRODUCT
Expression pattern of matrix metalloproteinases-2 and -9 and their tissue inhibitors in patients with chronic inflammatory demyelinating polyneuropathy
Cristina TassorelliEnrico AlfonsiMatteo GastaldiMaria MontanaGregorio CaimiVincenzo Di StefanoFilippo BrighinaMassimiliano TodiscoRosalia Lo PrestiBrigida FierroGiuseppe CosentinoAndrea CorteseAndrea Cortesesubject
medicine.medical_specialtyNeurologyChronic inflammatory demyelinating polyneuropathyCIDPDermatologyMatrix metalloproteinaseGastroenterologyTissue inhibitor of matrix metalloproteinase03 medical and health sciences0302 clinical medicineImmune systemExpression patternDownregulation and upregulationInternal medicineEndopeptidasesmedicineTIMPHumansIn patient030212 general & internal medicineMMPbusiness.industryGeneral Medicinemedicine.diseaseMatrix MetalloproteinasesPathophysiologyMatrix metalloproteinasePsychiatry and Mental healthMatrix Metalloproteinase 9Polyradiculoneuropathy Chronic Inflammatory DemyelinatingMatrix Metalloproteinase 2Settore MED/26 - NeurologiaNeurology (clinical)business030217 neurology & neurosurgerydescription
Background: Matrix metalloproteinases (MMPs) are a heterogeneous family of endopeptidases that play a role in many physiological functions, including the immune response. An imbalance between the activity of MMPs and their physiological tissue inhibitors (TIMPs) has been proposed in the pathophysiology of different autoimmune disorders. We aimed to assess the plasmatic levels of MMP-2, MMP-9, and their inhibitors TIMP-1 and -2 in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Subjects and methods: Twenty patients with CIDP and 20 age- and sex-matched healthy controls were enrolled. Plasma concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined by the enzyme-linked immunosorbent assay. Results: CIDP subjects had higher MMP-9 concentrations along with TIMP-1 downregulation when compared to controls, with the consequent increase in the MMP-9/TIMP-1 ratio (p<0.000002 for all measures). Conversely, the concentration of MMP-2 was lower in the CIDP group (p<0.01) without changes in the TIMP-2 concentration. The MMP-2/TIMP-2 ratio was decreased in the patients’ group (p<0.02). Discussion: We provide first preliminary evidence that the plasmatic pattern of MMPs and TIMPs is markedly altered in patients with CIDP. Future studies are needed to assess the potential usefulness of these new biomarkers in the clinical setting.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-10-01 | Neurological Sciences |